Asthma Clinical Trial
Official title:
Improving the Diagnosis of Pediatric Pneumonia at Hospital and Village Levels: A Multi-centre Indian Study
Pneumonia is the commonest cause of death in children worldwide, killing 1.5 million children
under the age of 5 years, every year. This is more than the number of children dying from
AIDS, malaria and tuberculosis combined. The current diagnostic and management protocols for
managing serious respiratory diseases in children are 30 years old and are greatly in need of
updating. The successful establishment of useful clinical management criteria for children
with respiratory diseases will have benefits for children in low resource regions around the
world. The goals of the study are:
- To determine if children with respiratory distress can be reliably diagnosed under
low-resource conditions.
- To identify the clinical tests that best differentiate pneumonia from wheezy diseases.
These will be used to establish updated diagnostic criteria for common pediatric lung
diseases that broaden the current pneumonia algorithm by adding another for wheezy
illnesses.
- The ultimate objective is to improve the management and outcome of acute respiratory
conditions in children.
- Investigators also wish to test the efficacy of a locally developed cell phone oximeter
probe in a low resource setting.
Study organisation. This is a prospective observational study run simultaneously in four
Indian public hospitals (King George Medical University, Lucknow; Regency Hospital, Kanpur;
Vanivilas Hospital, Bangalore; Bowring and Lady Curzon Hospital, Bangalore). The study
started in Oct 2012 to cover the Indian respiratory viral season. In order to maintain high
standards of data collection, a post-graduate research coordinator is employed at each
hospital. Because of the use of standardised scoring systems and the need for accurate
clinical data collection, a member from the Canadian team spent a week at each centre
familiarising local research team members with the study protocol and standardised scoring
systems. This was followed by a one week trial period of data collection and electronic
transmission of files to Canada.
Diagnostic definitions and standardised scores. The primary problem facing any study of
pneumonia is accurate diagnosis. The overlap of clinical and radiological findings between
severe viral infections, asthma and bacterial pneumonia can make it difficult to determine
which febrile tachypneic children have wheezy diseases and which ones would benefit from
antibiotic treatment. In many low-resource areas, this is further complicated by infectious
diseases, such as malaria and dengue, which can have similar presentations. Early WHO
tachypnea-based diagnostic protocols were intentionally over-sensitive to ensure that all
children with bacterial pneumonia received antibiotics. Later attempts were made to improve
the detection of wheezy diseases, by adding audible wheeze or acute bronchodilator response
to the basic criteria. However, these were shown to be imprecise, particularly amongst the
sickest children.
Investigators chose to formalize the diagnostic method described by Sachdev et al who
classified patients into four groups (pneumonia, wheezy disease, mixed and non-respiratory)
based on consultant review of a detailed history and examination plus a chest radiograph
(CXR). Investigators recorded 29 items from a protocol that included history, examination,
CXR and oximetry (see table). In order to combine results from data collection between
centres, standardised scoring systems for conscious level and auscultation findings were
used. For chest radiographs, a modification of the recently updated system recommended by the
WHO was used. During the one week preparatory period, the system was explained to all
involved ER physicians and pediatricians using examples and practice interpretation.
Study protocol. All children below 5 years age who present to the emergency rooms of the
study hospitals with cough or difficulty breathing of less than 5 days, are identified. If
their initial respiratory rate met WHO criteria for pneumonia, the study is explained by a
native speaker of their primary language and they are invited to enter the study. Families
are not paid to enrol but the study covers the cost of a CXR for every child plus travel
expenses for outpatients to return for review on day four. After enrolment, twenty nine
features of the child's history, examination and CXR are assessed by the ER physician and
recorded by the study coordinator(Table 2).
After reviewing the data, the ER physician is asked to place the child into one of four
diagnostic categories: pneumonia, wheezy disease (asthma and bronchiolitis), mixed (evidence
of pneumonia and wheeze) and non-respiratory (malaria, dengue etc). The ER physician is
solely responsible for subsequent management decisions. All study patients are reviewed four
days later by a qualified pediatrician who is blinded to the ER physician's CXR
interpretation and diagnosis. Based on a review of the clinical data at presentation, plus
subsequent course over 4 days and a second examination, the pediatrician places the patient
into one of the four diagnostic categories. This is considered the child's final diagnosis
for analysis.
Statistical analysis. Logistic regression analysis will be used to determine which of the
initial clinical variables had the best predictive power for pneumonia and asthma. The best
cut-off values for continuous variables were established using receiver operating curve
analysis. For each predictive variable, sensitivity, specificity plus positive and negative
predictive value will be calculated from conventional tables using standard equations. When
the predictive value of combining variables is tested, investigators will link them as 'A
and/or B'. This increases sensitivity but decreases specificity, compared to using 'A and B.'
Continuous variables will be displayed as mean +/- one standard deviation. Categorical
variables will be displayed with box and whisker plots where the whiskers represent full
range.
Table of investigations performed in the ER at presentation.
History Recorded details Cough yes/no Difficulty Breathing yes/no Lethargy yes/no Reduced
feeding yes/no Fever yes/no Previous similar episodes number Vaccinations number and type
Examination Recorded details Age months Weight weight for age 'z' score Temperature ⁰ Celsius
Heart rate beats/minute Respiratory rate breaths/minute Indrawing present/absent
Responsiveness score:
A fully alert V responds to voice P responds to pain U unconscious
Auscultation score:
Chest clear normal vesicular breath sounds Crackles coarse or fine inspiratory
crackles/rattles Wheeze high pitched whistling noise, inspiratory or expiratory Crackles and
wheeze both sounds present Bronchial breathing tracheal breath sounds heard over the lungs
Investigations Recorded details
CXR score: one or more of:
Normal ) Hyperinflation ) Minor patchy changes ) definitions, see table 3 Major patchy
changes ) Lobar changes ) Pleural fluid ) Oximetry % oxygen saturation
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|